Summary

Paroxysmal Nocturnal Hemoglobinuria Market – Scope of Report
TMR’s report on the global paroxysmal nocturnal hemoglobinuria market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global paroxysmal nocturnal hemoglobinuria market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global paroxysmal nocturnal hemoglobinuria market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the paroxysmal nocturnal hemoglobinuria market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global paroxysmal nocturnal hemoglobinuria market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global paroxysmal nocturnal hemoglobinuria market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global paroxysmal nocturnal hemoglobinuria market.

The report delves into the competitive landscape of the global paroxysmal nocturnal hemoglobinuria market. Key players operating in the global paroxysmal nocturnal hemoglobinuria market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global paroxysmal nocturnal hemoglobinuria market profiled in this report.

Key Questions Answered in Global paroxysmal nocturnal hemoglobinuria Market Report
• What is the sales/revenue generated by paroxysmal nocturnal hemoglobinuria across all regions during the forecast period?
• What are the opportunities in the global paroxysmal nocturnal hemoglobinuria market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Paroxysmal Nocturnal Hemoglobinuria Market – Research Objectives and Research Approach
The comprehensive report on the global paroxysmal nocturnal hemoglobinuria market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global paroxysmal nocturnal hemoglobinuria market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global paroxysmal nocturnal hemoglobinuria market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Paroxysmal Nocturnal Hemoglobinuria Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2020-2034
6.3.1. Medication
6.3.1.1. Eculizumab
6.3.1.2. Ravulizumab
6.3.2. Supplements
6.3.3. Blood Transfusion
6.3.4. Bone Marrow Transplant
6.3.5. Immunosuppressive Therapy
6.4. Market Attractiveness Analysis, by Treatment
7. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2020-2034
7.3.1. Hospitals & Clinics
7.3.2. Homecare Settings
7.3.3. Others (Research Institutes, etc.)
7.4. Market Attractiveness Analysis, by End-user
8. Global Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2020-2034
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Treatment, 2020-2034
9.3.1. Medication
9.3.1.1. Eculizumab
9.3.1.2. Ravulizumab
9.3.2. Supplements
9.3.3. Blood Transfusion
9.3.4. Bone Marrow Transplant
9.3.5. Immunosuppressive Therapy
9.4. Market Value Forecast, by End-user, 2020-2034
9.4.1. Hospitals & Clinics
9.4.2. Homecare Settings
9.4.3. Others (Research Institutes, etc.)
9.5. Market Value Forecast, by Country, 2020-2034
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By End-user
9.6.3. By Country
10. Europe Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Treatment, 2020-2034
10.3.1. Medication
10.3.1.1. Eculizumab
10.3.1.2. Ravulizumab
10.3.2. Supplements
10.3.3. Blood Transfusion
10.3.4. Bone Marrow Transplant
10.3.5. Immunosuppressive Therapy
10.4. Market Value Forecast, by End-user, 2020-2034
10.4.1. Hospitals & Clinics
10.4.2. Homecare Settings
10.4.3. Others (Research Institutes, etc.)
10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Treatment, 2020-2034
11.3.1. Medication
11.3.1.1. Eculizumab
11.3.1.2. Ravulizumab
11.3.2. Supplements
11.3.3. Blood Transfusion
11.3.4. Bone Marrow Transplant
11.3.5. Immunosuppressive Therapy
11.4. Market Value Forecast, by End-user, 2020-2034
11.4.1. Hospitals & Clinics
11.4.2. Homecare Settings
11.4.3. Others (Research Institutes, etc.)
11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Treatment, 2020-2034
12.3.1. Medication
12.3.1.1. Eculizumab
12.3.1.2. Ravulizumab
12.3.2. Supplements
12.3.3. Blood Transfusion
12.3.4. Bone Marrow Transplant
12.3.5. Immunosuppressive Therapy
12.4. Market Value Forecast, by End-user, 2020-2034
12.4.1. Hospitals & Clinics
12.4.2. Homecare Settings
12.4.3. Others (Research Institutes, etc.)
12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Treatment, 2020-2034
13.3.1. Medication
13.3.1.1. Eculizumab
13.3.1.2. Ravulizumab
13.3.2. Supplements
13.3.3. Blood Transfusion
13.3.4. Bone Marrow Transplant
13.3.5. Immunosuppressive Therapy
13.4. Market Value Forecast, by End-user, 2020-2034
13.4.1. Hospitals & Clinics
13.4.2. Homecare Settings
13.4.3. Others (Research Institutes, etc.)
13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2023)
14.3. Company Profiles
14.3.1. Alexion Pharmaceuticals, Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Apellis Pharmaceuticals
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Genentec, Inc.
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Novartis AG
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. The Takeda Pharmaceutical Company Limited
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Kira Pharmaceuticals
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. F. Hoffman-La Roche AG
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Akari Therapeutics PLC
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. Omeros Corporation
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Regeneron Pharmaceuticals, Inc.
14.3.10.1. Company Overview
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview